- Browse by Author
Browsing by Author "Kircik, Leon"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1(Elsevier, 2020) Gelfand, Joel M.; Armstrong, April W.; Bell, Stacie; Anesi, George L.; Blauvelt, Andrew; Calabrese, Cassandra; Dommasch, Erica D.; Feldman, Steve R.; Gladman, Dafna; Kircik, Leon; Lebwohl, Mark; Lo Re, Vincent, III; Martin, George; Merola, Joseph F.; Scher, Jose U.; Schwartzman, Sergio; Treat, James R.; Van Voorhees, Abby S.; Ellebrecht, Christoph T.; Fenner, Justine; Ocon, Anthony; Syed, Maha N.; Weinstein, Erica J.; Smith, Jessica; Gondo, George; Heydon, Sue; Koons, Samantha; Ritchlin, Christopher T.; Medicine, School of MedicineObjective To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. Study design A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. Results The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus. Limitations The evidence behind many guidance statements is limited in quality. Conclusion These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.Item National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments(Elsevier, 2021-05) Gelfand, Joel M.; Armstrong, April W.; Bell, Stacie; Anesi, George L.; Blauvelt, Andrew; Calabrese, Cassandra; Dommasch, Erica D.; Feldman, Steven R.; Gladman, Dafna; Kircik, Leon; Lebwohl, Mark; Lo Re, Vincent, III; Martin, George; Merola, Joseph F.; Scher, Jose U.; Schwartzman, Sergio; Treat, James R.; Van Voorhees, Abby S.; Ellebrecht, Christoph T.; Fenner, Justine; Ocon, Anthony; Syed, Maha N.; Weinstein, Erica J.; Gondo, George; Heydon, Sue; Koons, Samantha; Ritchlin, Christopher T.; Dermatology, School of MedicineObjective To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. Study Design The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted. Results The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus. Limitations The evidence behind many guidance statements is variable in quality and/or quantity. Conclusions These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.Item Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II Post-hoc Analysis(Matrix Medical Communications, 2021-04) Baldwin, Hilary E.; Green, Lawrence J.; Kircik, Leon; Guenin, Eric Pierre; Loncaric Forest, Anya; Pillai, Radhakrishnan; Dermatology, School of MedicineBACKGROUND: In a Phase II study, tazarotene 0.045% lotion was statistically superior to vehicle and comparable to tazarotene 0.1% cream in reducing acne lesions, with fewer treatment-related adverse events (TEAEs) than the cream. OBJECTIVE: We analyzed data from the aforementioned study post-hoc to evaluate the effects of sex on treatment outcomes. METHODS: Participants aged 12 years or older with moderate-to-severe acne were randomized to tazarotene (0.045% lotion or 0.1% cream) or vehicle (lotion or cream) for 12 weeks of double-blind treatment. Outcomes analyzed in male and female subgroups included changes from baseline in inflammatory/noninflammatory lesions and TEAEs. RESULTS: In the intent-to-treat population (94 males and 116 females), reductions in lesion count were greater with tazarotene (lotion or cream) than with vehicle. In participants receiving tazarotene 0.045% lotion, the least-squares mean percent changes from baseline to Week 12 were greater in females than males, but the differences were not statistically significant (inflammatory [-70.3% vs. -56.2%]; noninflammatory [-60.0% vs. -53.2%]). In both females and males, the TEAE incidence was lower with tazarotene 0.045% lotion than 0.1% cream. CONCLUSION: Tazarotene 0.045% lotion substantially reduced acne lesions in both female and male participants. This newest tazarotene formulation might benefit patients who cannot tolerate older formulations or other topical retinoids. Given the relatively small size of this study, however, the results of this post-hoc analysis are intended to be exploratory in nature.